莫西沙星序贯治疗老年社区获得性肺炎的药物经济学评价

目的对莫西沙星两种不同给药方案治疗老年社区获得性肺炎进行药物经济学评价。方法将80例患者随机分为莫西沙星序贯治疗组(序贯组)和莫西沙星静脉滴注组(对照组),每组各40例。序贯治疗组给予莫西沙星注射液0.4 g,静脉滴注,1次.d-1,5 d后,病情好转,改为莫西沙星片0.4 g,口服,1次.d-1,总疗程11 d;对照组给予莫西沙星注射液0.4 g,静脉滴注,1次.d-1,总疗程11 d。评价临床疗效及药物经济学。结果序贯组和对照组痊愈率分别为57.5%、62.5%(P0.05),有效率分别为90.0%、92.5%(P0.05),不良反应发生率分别为7.5%、10%(P0.05)。序贯治疗组的成本-效果比为2 000.0,低于对照组(3 864.9)。结论莫西沙星序贯治疗老年社区获得性肺炎疗效高、安全、经济。

Pharmacoeconomic efficacy of moxifloxacin sequential therapy for community-acquired pneumonia in elderly patients

Objective To evaluate pharmacoeconomic efficacy of two different dosage regimens of moxifloxacin in the treatment of community acquired pneumonia in elderly patients.Method A total of 80 patients were randomly enrolled into 2 groups：moxifloxacin injection followed by tablet（sequential group） and moxifloxacin injection group（control group）.Moxifloxacin was administered by intravenous infusion,400 mg/250 ml once daily for 11 days in control group（n=40）.In sequential group（n=40）,moxifloxacin was given by intravenous infusion 400 mg/250 ml,once daily for 5 days,followed by oral administration at the same dose.The total treatment duration was also 11 days.After the end of therapy,to the clinical efficacy and pharmacoeconomic efficacy were evaluation.Results For sequential group vs.control group,the cute rate was 57.5% vs 62.5%（P0.05）,the effective rate was 90.0% vs 92.5%（P0.05）,and the incidence of ADRs was 7.5% vs 10%（P0.05）.The cost-effectiveness of sequential group（2 000.0） was lower than control group（3864.9）.Conclusion Moxifloxacin sequential therapy is efficacious,safety and cost-effective for community-acquired pneumonia in elderly patients.